Command Palette

Search for a command to run...

Clinical Trials · NCT01388920

Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting

TerminatedPhase 2Tesamorelin (Prohibited)
Phase
Phase 2
Recruitment status
Terminated
Sponsor
Theratechnologies
Enrollment
3
Start date
Sep 2011
Locations
See registry
Primary endpoint
Change From Baseline in Lean Body Mass at 6 Months
View Tesamorelin compound reference